

CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109

Overview

2024/07/11 16:30:13

Price
0.4275 EURDifference ▲ 0.35% (0.00)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | NL0014040206 |
| Symbol | CNTG |
| Exchange | Duesseldorf |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 13 EUR |
| Benchmark | GERMANY DAX |

Market data

| | |
|-------------------|--------------------|
| Bid (Bid size) | 0.4425 EUR (2,280) |
| Ask (Ask size) | 0.4775 EUR (2,280) |
| Open | 0.434 EUR |
| High | 0.434 EUR |
| Low | 0.4275 EUR |
| Close (prev. day) | 0.426 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |

Futures and Options

| | |
|-----------------|---|
| Related Futures | - |
| Related Options | - |

PDF Downloads

Company report: CENTOGENE NV COM EUR0.12 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | | on market | |
|------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/06/21 |  | Global Equity Ratings |  |
| 2024/06/14 |  | Global Equity Ratings |  |
| 2024/05/29 |  | Global Equity Ratings |  |
| 2024/04/26 |  | Global Equity Ratings |  |
| 2024/04/03 |  | Global Equity Ratings |  |

Details

2024/07/11 16:30:13

Price
0.4275 EUR

Difference ▲ 0.35% (0.00)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | NL0014040206 |
| Symbol | CNTG |
| Exchange | Duesseldorf |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 13 EUR |
| Benchmark | GERMANY DAX |

Market data

| | |
|-------------------|--------------------|
| Bid (Bid size) | 0.4425 EUR (2,280) |
| Ask (Ask size) | 0.4775 EUR (2,280) |
| Open | 0.434 EUR |
| High | 0.434 EUR |
| Low | 0.4275 EUR |
| Close (prev. day) | 0.426 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|---------|
| Perf (%) | -57.61% | -65.65% | -95.58% |
| Perf (abs.) | -0.58 | -0.81 | -9.21 |
| Beta | 0.64 | 0.75 | 0.72 |
| Volatility | 72.42 | 69.76 | 103.12 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 0.4128 EUR (0) |
| Ø price 30 days Ø volume 30 days (pcs.) | 0.3565 EUR (0) |
| Ø price 100 days Ø volume 100 days (pcs.) | 0.4751 EUR (15) |
| Ø price 250 days Ø volume 250 days (pcs.) | 0.7927 EUR (8) |
| YTD High date | 1.1300 EUR (2024/01/18) |
| YTD Low date | 0.3135 EUR (2024/05/17) |
| 52 Weeks High date | 1.4150 EUR (2023/07/12) |
| 52 Weeks Low date | 0.3135 EUR (2024/05/17) |

All listings for CENTOGENE NV COM EUR0.12

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------|------------|-------|------------|-----------------------|------------------|
| Tradegate | 2024/07/11 | 17:32 | 0.45 EUR | 0.01 | 4 |
| Stuttgart | 2024/07/11 | 08:01 | 0.3925 EUR | 0.00 | 1 |
| Nasdaq | 2024/07/11 | 18:36 | 0.49 USD | 0.02 | 130 |
| Munich | 2024/07/11 | 08:01 | 0.4345 EUR | 0.00 | 1 |
| Hamburg | 2024/07/11 | 08:16 | 0.42 EUR | 0.00 | 1 |

| | | | | | | |
|-------------|----------------|-------|------------|------|--|----|
| | 11 | | | | | |
| Frankfurt | 2024/07/ 11 | 08:09 | 0.42 EUR | 0.00 | | 1 |
| Duesseldorf | 2024/07/ 11 | 16:30 | 0.4275 EUR | 0.00 | | 4 |
| Berlin | 2024/07/ 11 | 17:42 | 0.46 EUR | 0.00 | | 14 |

Company profile

Company Logo



Contact Details

CENTOGENE NV

- -

Am Strande 7 - 18055 Rostock

Telefon: +49-381-80113400

Fax: +381-80113401

E-mail: -

PDF Downloads

Company report: CENTOGENE NV
COM EUR0.12



Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Members of Management Board

| | |
|-------------------|-------------------------------|
| Kim Stratton | Chairman of Managing Board |
| Ian Rentsch | Member of Executive Committee |
| Miguel Coego Rios | Member of Executive Committee |
| Peter Bauer | Member of Executive Committee |

Board of directors

| | |
|------------------|-------------------------------|
| Peer Schatz | Chairman of Supervisory Board |
| Eric Sou tre | Member of Supervisory Board |
| Hubert Birner | Member of Supervisory Board |
| Jonathan Sheldon | Member of Supervisory Board |
| Guido Prehn | Member of Supervisory Board |
| Mary Sheahan | Member of Supervisory Board |